NRx Pharmaceuticals, Inc. (NRXP) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Wilmington, DE, 미국. 현재 CEO는 Jonathan C. Javitt.
NRXP 을(를) 보유 IPO 날짜 2017-12-04, 2 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $43.56M.
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
